ABSTRACT
Intervention packages may result in a greater public health impact than single interventions. Understanding the separate impact of each component in the overall package effectiveness can improve intervention delivery. We adapted an approach to evaluate the effects of a time-varying intervention package in a network-randomized study. In some network-randomized studies, only a subset of participants in exposed networks receive the intervention themselves. The spillover effect contrasts average potential outcomes if a person was not exposed themselves under intervention in the network versus no intervention in a control network. We estimated effects of components of the intervention package in HIV Prevention Trials Network 037, a Phase III network-randomized HIV prevention trial among people who inject drugs and their risk networks using Marginal Structural Models to adjust for time-varying confounding. The index participant in an intervention network received a peer education intervention initially at baseline, then boosters at 6 and 12 months. All participants were followed to ascertain HIV risk behaviors. There were 560 participants with at least one follow-up visit, 48% of whom were randomized to the intervention, and 1,598 participant-visits were observed. The spillover effect of the boosters in the presence of initial peer education training was a 39% rate reduction (Rate Ratio = 0.61; 95% confidence interval= 0.43, 0.87). These methods will be useful to evaluate intervention packages in studies with network features.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
ALB, SHV, LF and DS were supported by National Institutes of Health (NIH) grant R01MH134715. ALB and SRF were supported by an Avenir Award DP2DA046856 from National Institute on Drug Abuse of the NIH. RUH-R, ALB, and DS were supported by National Institutes of Health (NIH) grant R01AI112339. RUH-R, and DS were also supported by NIH grant P30MH062294-18. ALB and DS were also supported by NIH grant DP1ES025459, while SHV was supported by NIH grant P30MH062294. JJL was supported by the National Science Foundation (NSF) grant DMS 1854934. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the National Science Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Rhode Island IRB. DETERMINATION OF NOT HUMAN SUBJECT RESEARCH.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
CONFLICTS OF INTEREST: The authors have no conflicts of interest to declare.
FUNDING: ALB, SHV, LF and DS were supported by National Institutes of Health (NIH) grant R01MH134715. ALB and SRF were supported by an Avenir Award DP2DA046856 from National Institute on Drug Abuse of the NIH. RUH-R, ALB, and DS were supported by National Institutes of Health (NIH) grant R01AI112339. RUH-R, and DS were also supported by NIH grant P30MH062294-18. ALB and DS were also supported by NIH grant DP1ES025459, while SHV was supported by NIH grant P30MH062294. JJL was supported by the National Science Foundation (NSF) grant DMS 1854934. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the National Science Foundation.
DATA AND COMPUTING CODE AVAILABILITY: Example SAS code used to fit the models pre-sented in this paper can be found in the Supplement Appendix E. The HPTN 037 study data sets are publicly available and can be requested from the Statistical Center for HIV/AIDS Research and Prevention through the ATLAS Science Portal through https://atlas.scharp.org/cpas.
The revision includes a sensitivity analysis for effect modification by study visit month, more details about the modeling, and clarification of the model used in the HPTN 037 study data. We also clarified the motivating study in relation to the methods, further explained the assumptions, and improved the presentation of the estimands and model.
Data Availability
Example SAS code used to fit the models presented in this paper can be found in the Supplement Appendix E. The HPTN 037 study data sets are publicly available and can be requested from the Statistical Center for HIV/AIDS Research and Prevention through the ATLAS Science Portal through https://atlas.scharp.org/cpas/.
ABBREVIATIONS
- (CI)
- Confidence interval
- (GEEs)
- Generalized estimating equations
- (HPTN)
- HIV Prevention Trials Network
- (HIV)
- Human Immunodeficiency Virus
- (PWID)
- People who inject drugs
- (RR)
- Risk/Rate ratio
